

# Basic pharmacodynamics of antibacterials with clinical glycopeptides, and linezolid

Infectious Disease Clinics of North America

17, 479-501

DOI: 10.1016/s0891-5520(03)00065-5

Citation Report

#	ARTICLE	IF	CITATIONS
1	Pharmacodynamics of Telavancin (TD-6424), a Novel Bactericidal Agent, against Gram-Positive Bacteria. Antimicrobial Agents and Chemotherapy, 2004, 48, 3043-3050.	3.2	139
2	Effect of Ertapenem Protein Binding on Killing of Bacteria. Antimicrobial Agents and Chemotherapy, 2004, 48, 3419-3424.	3.2	41
3	Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nature Reviews Microbiology, 2004, 2, 289-300.	28.6	825
4	Overview of newer antimicrobial formulations for overcoming pneumococcal resistance. The American Journal of Medicine: Supplement, 2004, 117, 16-22.	1.6	11
5	Pharmacodynamics of antimicrobial drugs. Infectious Disease Clinics of North America, 2004, 18, 451-465.	5.1	195
6	Principles of use of antibacterial agents. Infectious Disease Clinics of North America, 2004, 18, 435-450.	5.1	17
7	Anti-infective pharmacodynamics â€“ maximizing efficacy, minimizing toxicity. Drug Discovery Today: Therapeutic Strategies, 2004, 1, 505-512.	0.5	6
8	Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin. Infectious Disease Clinics of North America, 2004, 18, 651-668.	5.1	41
9	Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Current Opinion in Pharmacology, 2004, 4, 471-478.	3.5	96
10	Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia*. Critical Care Medicine, 2005, 33, 1529-1533.	0.9	164
11	Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance. Clinical Microbiology and Infection, 2005, 11, 4-16.	6.0	97
12	New recommendations for vancomycin dosage for patients with MRSA pneumonia with various degrees of renal function impairment. Journal of Infection and Chemotherapy, 2005, 11, 182-188.	1.7	2
13	Four case studies to highlight some opportunities and challenges in developing anti-bacterial and anti-fungal agents. Pharmaceutical Statistics, 2005, 4, 253-265.	1.3	2
14	Pharmacokinetics of imipenem in healthy volunteers following administration by 2 h or 0.5 h infusion. Journal of Antimicrobial Chemotherapy, 2005, 56, 1163-1165.	3.0	28
15	Efficacy of Telavancin (TD-6424), a Rapidly Bactericidal Lipoglycopeptide with Multiple Mechanisms of Action, in a Murine Model of Pneumonia Induced by Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2005, 49, 4344-4346.	3.2	83
16	Evaluation by Monte Carlo Simulation of the Pharmacokinetics of Two Doses of Meropenem Administered Intermittently or as a Continuous Infusion in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2005, 49, 1881-1889.	3.2	87
18	Activity of three Î²-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus. Journal of Antimicrobial Chemotherapy, 2005, 55, 897-904.	3.0	50
19	Comparison of the Pharmacodynamics of Meropenem in Patients with Ventilator-Associated Pneumonia following Administration by 3-Hour Infusion or Bolus Injection. Antimicrobial Agents and Chemotherapy, 2005, 49, 1337-1339.	3.2	138

#	ARTICLE	IF	CITATIONS
20	Application of Pharmacokinetics and Pharmacodynamics to Antimicrobial Therapy of Community-Acquired Respiratory Tract Infections. <i>Respiration</i> , 2005, 72, 561-571.	2.6	11
21	Penetration of Piperacillin and Tazobactam into Inflamed Soft Tissue of Patients with Diabetic Foot Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4368-4371.	3.2	23
22	Use of Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Phase 2 and 3 Dosing Strategies for Doripenem. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3944-3947.	3.2	123
23	Guidelines for the Selection of Antibacterial Therapy in Children. <i>Pediatric Clinics of North America</i> , 2005, 52, 869-894.	1.8	12
24	Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 333-340.	3.0	74
25	A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. <i>Clinical Therapeutics</i> , 2005, 27, 762-772.	2.5	55
26	Use of Monte Carlo simulation to assess the pharmacodynamics of $\beta$ -lactams against pseudomonas aeruginosa infections in children: A report from the OPTAMA program. <i>Clinical Therapeutics</i> , 2005, 27, 1820-1830.	2.5	30
27	Postantibiotic effect of antimicrobial combinations on multidrug-resistant <i>Pseudomonas aeruginosa</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 51, 113-117.	1.8	23
28	Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 171, 388-416.	5.6	6,817
29	Antimicrobial Therapy in Critically Ill Patients. <i>Clinical Pharmacokinetics</i> , 2005, 44, 1009-1034.	3.5	316
30	New dosing strategies for antibacterial agents in the neonate. <i>Seminars in Fetal and Neonatal Medicine</i> , 2005, 10, 185-194.	2.3	88
31	Clinical Implications of Pharmacokinetics and Pharmacodynamics of Fluoroquinolones. <i>Clinical Infectious Diseases</i> , 2005, 41, S127-S135.	5.8	69
32	Solutions to the Problem of Bacterial Resistance. <i>Treatments in Respiratory Medicine</i> , 2005, 4, 25-30.	1.4	3
33	In Vitro Susceptibility Testing Versus In Vivo Effectiveness. <i>Medical Clinics of North America</i> , 2006, 90, 1077-1088.	2.5	18
34	Pharmacokinetics and pharmacodynamics of antibiotics revisited in lungs. <i>Antibiotiques</i> , 2006, 8, 232-241.	0.1	1
35	Optimizing Antimicrobial Therapy for Gram-Positive Bloodstream Infections in Patients on Hemodialysis. <i>Advances in Chronic Kidney Disease</i> , 2006, 13, 259-270.	1.4	11
37	Dosage des Antibiotiques en Réanimation: quand et comment demander et interpréter les tests?. <i>Reanimation: Journal De La Societe De Reanimation De Langue Francaise</i> , 2006, 15, 187-192.	0.1	16
38	Antibacterial Dosing in Intensive Care. <i>Clinical Pharmacokinetics</i> , 2006, 45, 755-773.	3.5	247

#	ARTICLE	IF	CITATIONS
39	Gram-Positive Cocci Infections in Intensive Care. <i>Drugs</i> , 2006, 66, 751-768.	10.9	9
40	The effect of food on plasma and tissue concentrations of linezolid after multiple doses. <i>International Journal of Antimicrobial Agents</i> , 2006, 27, 108-112.	2.5	21
41	Community-acquired methicillin-resistant <i>Staphylococcus aureus</i> infections. <i>International Journal of Antimicrobial Agents</i> , 2006, 27, 87-96.	2.5	152
42	Pharmacodynamics: Relation to antimicrobial resistance. <i>American Journal of Infection Control</i> , 2006, 34, S38-S45.	2.3	53
43	Pharmacodynamics: Relation to Antimicrobial Resistance. <i>American Journal of Medicine</i> , 2006, 119, S37-S44.	1.5	76
44	Hospital-acquired pneumonia in the 21st century: a review of existing treatment options and their impact on patient care. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1555-1569.	1.8	26
46	Teicoplanin Population Pharmacokinetic Analysis in Hospitalized Patients. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 737-743.	2.0	32
48	Clinical implications and treatment of multiresistant <i>Streptococcus pneumoniae</i> pneumonia. <i>Clinical Microbiology and Infection</i> , 2006, 12, 31-41.	6.0	61
49	Diagnosis and treatment of catheter-related infections in paediatric oncology: an update. <i>Clinical Microbiology and Infection</i> , 2006, 12, 606-620.	6.0	77
50	Pharmacokinetics of cefovecin in cats. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2006, 29, 513-524.	1.3	42
51	Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level. <i>Journal of Infection and Chemotherapy</i> , 2006, 12, 185-189.	1.7	34
52	The role of pharmacodynamic research in the assessment and development of new antibacterial drugs. <i>Biochemical Pharmacology</i> , 2006, 71, 1057-1065.	4.4	19
53	Optimizing Antibiotic Treatment for Ventilator-Associated Pneumonia. <i>Pharmacotherapy</i> , 2006, 26, 204-213.	2.6	27
54	Potential Impact of Vancomycin Pulmonary Distribution on Treatment Outcomes in Patients with Methicillin-Resistant <i>Staphylococcus aureus</i> Pneumonia. <i>Pharmacotherapy</i> , 2006, 26, 539-550.	2.6	68
55	Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1402-1406.	0.7	31
56	Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 1346-1360.	1.0	17
57	Rational Use of Antimicrobials in Infants in Primary Care of Bahrain. <i>Journal of Tropical Pediatrics</i> , 2006, 52, 390-393.	1.5	3
58	Effect of Treatment Duration on Pharmacokinetic/Pharmacodynamic Indices Correlating with Therapeutic Efficacy of Ceftazidime in Experimental <i>Klebsiella pneumoniae</i> Lung Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2919-2925.	3.2	25

#	ARTICLE	IF	CITATIONS
59	The Role of Vancomycin in the Treatment Paradigm. <i>Clinical Infectious Diseases</i> , 2006, 42, S51-S57.	5.8	149
60	Serum and Cerebrospinal Fluid Concentrations of Linezolid in Neurosurgical Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3971-3976.	3.2	98
61	Pharmacodynamics of a New Cephalosporin, PPI-0903 (TAK-599), Active against Methicillin-Resistant <i>Staphylococcus aureus</i> in Murine Thigh and Lung Infection Models: Identification of an In Vivo Pharmacokinetic-Pharmacodynamic Target. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1376-1383.	3.2	135
62	The Antimicrobial Therapy Puzzle: Could Pharmacokinetic-Pharmacodynamic Relationships Be Helpful in Addressing the Issue of Appropriate Pneumonia Treatment in Critically Ill Patients?. <i>Clinical Infectious Diseases</i> , 2006, 42, 1764-1771.	5.8	133
63	Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 462-465.	3.0	73
64	Clinical Correlation of the CLSI Susceptibility Breakpoint for Piperacillin-Tazobactam against Extended-Spectrum-β-Lactamase-Producing <i>Escherichia coli</i> and <i>Klebsiella</i> Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2244-2247.	3.2	72
65	Population Pharmacokinetic Analysis of Panipenem/Betamipron in Patients with Various Degrees of Renal Function. <i>Chemotherapy</i> , 2006, 52, 245-253.	1.6	5
66	Pharmacodynamic Evaluation of the Intracellular Activities of Antibiotics against <i>Staphylococcus aureus</i> in a Model of THP-1 Macrophages. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 841-851.	3.2	228
67	Antimicrobial Pharmacodynamics in Theory and Clinical Practice. , 0, , .		33
68	Antimicrobial Resistance in <i>Haemophilus influenzae</i> . <i>Clinical Microbiology Reviews</i> , 2007, 20, 368-389.	13.6	368
69	Comparative Study of the Effects of Pyridoxine, Rifampin, and Renal Function on Hematological Adverse Events Induced by Linezolid. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2559-2563.	3.2	58
70	Pharmacokinetics of Aztreonam in Healthy Subjects and Patients with Cystic Fibrosis and Evaluation of Dose-Exposure Relationships Using Monte Carlo Simulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3049-3055.	3.2	50
71	In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1633-1642.	3.2	102
72	Single-Dose Oral Amoxicillin or Linezolid for Prophylaxis of Experimental Endocarditis Due to Vancomycin-Susceptible and Vancomycin-Resistant <i>Enterococcus faecalis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1661-1665.	3.2	6
73	Pharmacokinetics of Penicillin G in Infants with a Gestational Age of Less than 32 Weeks. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3720-3725.	3.2	23
74	Vancomycin Disposition and Penetration into Ventricular Fluid of the Central Nervous System following Intravenous Therapy in Patients with Cerebrospinal Devices. <i>Pediatric Neurosurgery</i> , 2007, 43, 449-455.	0.7	24
75	Once-Weekly Micafungin Therapy Is as Effective as Daily Therapy for Disseminated Candidiasis in Mice with Persistent Neutropenia. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 968-974.	3.2	102
76	Concentration-Effect Relationship of Ceftazidime Explains Why the Time above the MIC Is 40 Percent for a Static Effect In Vivo. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3449-3451.	3.2	67

#	ARTICLE	IF	CITATIONS
77	Documento de Consenso sobre pneumonia nosocomial11Sociedade Portuguesa de Pneumologia e Sociedade Portuguesa de Cuidados Intensivos / Portuguese Society of Pulmonology and Intensive Care Society,22O presente documento Â© simultaneamente publicado na Revista Portuguesa de Medicina Intensiva (2007; 14(1):7-30) / This work is published simultaneously in the Portuguese Journal of Intensive Care Medicine (2007; 14(1):7-30). Part II: Antibiotic ChoiceâŽŽFor the full text of the STS Guideline on Antibiotic Prophylaxis in Cardiac Surgery, as well as other titles in the STS Practice Guideline Series, visit <a href="http://www.sts.org/sections/aboutthesociety/practiceguidelines/">http://www.sts.org/sections/aboutthesociety/practiceguidelines/</a> at the official STS website ( <a href="http://www.sts.org">www.sts.org</a> ). Annals of Thoracic Surgery, 2007, 83, 1569-1576.	0.7	17
78	Oral Î²-lactams applied to uncomplicated infections of skin and skin structures. Diagnostic Microbiology and Infectious Disease, 2007, 57, S55-S65.	1.3	369
79	Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate. Diagnostic Microbiology and Infectious Disease, 2007, 57, S5-S12.	1.8	37
81	Consensus document on nosocomial pneumonia. Revista Portuguesa De Pneumologia, 2007, 13, 419-486.	0.7	10
82	Pharmacokinetic and Pharmacodynamic Aspects of Antibiotic Use in High-Risk Populations. Infectious Disease Clinics of North America, 2007, 21, 821-846.	5.1	27
83	Linezolid: effectiveness and safety for approved and off-label indications. Expert Opinion on Pharmacotherapy, 2007, 8, 2381-2400.	1.8	32
85	Peritoneal penetration and pharmacodynamic exposure of intravenous cefozopran in abdominal surgery patients. International Journal of Antimicrobial Agents, 2007, 30, 352-355.	2.5	15
86	Combating resistance: application of the emerging science of pharmacokinetics and pharmacodynamics. International Journal of Antimicrobial Agents, 2007, 30, 122-126.	2.5	9
87	Hospital-Acquired Pneumonia Caused byStaphylococcus aureus. , 0, , 107-129.		0
89	Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. British Journal of Clinical Pharmacology, 2007, 63, 100-109.	2.4	49
90	Preparation of aromatic Î²-Selenolactams and their bioactivities as agricultural chemicals. Archives of Pharmacal Research, 2007, 30, 938-944.	6.3	6
91	Peritoneal pharmacokinetics of cefepime in laparotomy patients with inflammatory bowel disease, and dosage considerations for surgical intra-abdominal infections based on pharmacodynamic assessment. Journal of Infection and Chemotherapy, 2008, 14, 110-116.	1.7	5
92	Ciprofloxacin pharmacokinetics in critically ill patients: A prospective cohort study. Journal of Critical Care, 2008, 23, 422-430.	2.2	94
93	Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis. International Journal of Antimicrobial Agents, 2008, 32, 455-458.	2.5	605
94	Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimens. International Journal of Antimicrobial Agents, 2008, 32, 294-301.e7.	2.5	87
95	Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. Journal of Antimicrobial Chemotherapy, 2008, 61, 382-388.	3.0	78
96	Pharmacokinetics and Pharmacodynamic Assessment of Imipenem in the Intraperitoneal Fluid of Abdominal Surgery Patients. Chemotherapy, 2008, 54, 131-139.	1.6	16

#	ARTICLE	IF	CITATIONS
97	Linezolid for the treatment of skin and soft-tissue infections. Expert Review of Dermatology, 2008, 3, 539-548.	0.3	1
98	In Vivo Pharmacodynamics of Ceftobiprole against Multiple Bacterial Pathogens in Murine Thigh and Lung Infection Models. Antimicrobial Agents and Chemotherapy, 2008, 52, 3492-3496.	3.2	76
99	Efficacies of Ceftobiprole Medocaril and Comparators in a Rabbit Model of Osteomyelitis Due to Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2008, 52, 1618-1622.	3.2	29
100	Temocillin revived. Journal of Antimicrobial Chemotherapy, 2008, 63, 243-245.	3.0	107
101	The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. Expert Opinion on Pharmacotherapy, 2008, 9, 561-575.	1.8	46
102	Does sugar cause clotting? Intensive insulin treatment and activation of coagulation*. Critical Care Medicine, 2008, 36, 1657-1658.	0.9	2
103	Trust one who has gone through it*. Critical Care Medicine, 2008, 36, 1643-1644.	0.9	5
104	Antibiotic resistance—What's dosing got to do with it?. Critical Care Medicine, 2008, 36, 2433-2440.	0.9	299
105	Atrial fibrillation in the critically ill: Common sense for a common problem*. Critical Care Medicine, 2008, 36, 1681-1682.	0.9	5
106	Lost in (knowledge) translation: "All breakthrough, no follow through"*. Critical Care Medicine, 2008, 36, 1654-1655.	0.9	10
107	Continuous infusion of $\beta$ -lactams in the intensive care unit—Best way to hit the target?*. Critical Care Medicine, 2008, 36, 1663-1664.	0.9	15
108	E-CPR — Is there E-nough E-vidence to reach a "tipping point" for rapid deployment?*. Critical Care Medicine, 2008, 36, 1679-1681.	0.9	4
109	What is the score with mortality predictions in acute lung injury?*. Critical Care Medicine, 2008, 36, 1644-1646.	0.9	1
110	Ertapenem clearance during modeled continuous renal replacement therapy. International Journal of Artificial Organs, 2008, 31, 1027-1034.	1.4	30
111	Can B-type natriuretic peptide liberate us from the task of mechanical ventilation weaning?*. Critical Care Medicine, 2008, 36, 1646-1647.	0.9	1
112	The interleukin-6 gene and critical illness: Is inflammatory gene variation the key to personalized medicine in the intensive care unit?*. Critical Care Medicine, 2008, 36, 1647-1649.	0.9	2
113	The insulin, glucose, ischemia, and inflammation conundrum*. Critical Care Medicine, 2008, 36, 1673-1674.	0.9	1
114	From acute renal failure to acute kidney injury: Emerging concepts*. Critical Care Medicine, 2008, 36, 1641-1642.	0.9	14



#	ARTICLE	IF	CITATIONS
115	Strategies to reduce neuronal cell death in bacterial meningitis*. Critical Care Medicine, 2008, 36, 1678-1679.	0.9	1
116	Hydroxyethyl starch: Under the microscope*. Critical Care Medicine, 2008, 36, 1670-1671.	0.9	0
117	Pyrexia of uncertain overtones*. Critical Care Medicine, 2008, 36, 1669-1670.	0.9	0
118	Flow or no flow: That is the question!*. Critical Care Medicine, 2008, 36, 1677-1678.	0.9	0
119	Novel molecular strategy to prevent pulmonary edema*. Critical Care Medicine, 2008, 36, 1671-1673.	0.9	1
120	Teasing and skinning muscles in sepsis research*. Critical Care Medicine, 2008, 36, 1674-1675.	0.9	0
121	Continuous renal replacement therapy-induced alkalosis in intensive care unit patients: The questions start here*. Critical Care Medicine, 2008, 36, 1665-1666.	0.9	2
122	Moving toward preventive therapy in acute lung injury*. Critical Care Medicine, 2008, 36, 1666-1667.	0.9	0
123	Corticosteroids and septic shock: A new episode of a never-ceasing story?*. Critical Care Medicine, 2008, 36, 1658-1659.	0.9	0
124	The transfusion of pre storage leukoreduced packed red blood cells to injured patients*. Critical Care Medicine, 2008, 36, 1661-1662.	0.9	4
125	What do families know? A question of interpretation*. Critical Care Medicine, 2008, 36, 1683-1684.	0.9	0
126	Between critical illness and hospital discharge: Prolonged acute mechanical ventilation*. Critical Care Medicine, 2008, 36, 1651-1652.	0.9	2
127	Hypothermia hype: Is it worth it?*. Critical Care Medicine, 2008, 36, 1676-1677.	0.9	3
128	Should sedation be standardized in the intensive care unit?*. Critical Care Medicine, 2008, 36, 1649-1651.	0.9	15
129	Delayed gastric emptying in critical illness: Is enhanced enterogastric inhibition with cholecystokinin and peptide YY involved?*. Critical Care Medicine, 2008, 36, 1655-1656.	0.9	2
130	Genes and sepsis: How tight is the fit?*. Critical Care Medicine, 2008, 36, 1652-1654.	0.9	3
131	Life after intensive care—It's life—but not as we know it!*. Critical Care Medicine, 2008, 36, 1668-1669.	0.9	6
132	Calcitonin peptides—The mediators in sepsis or just another fairy tale?*. Critical Care Medicine, 2008, 36, 1684-1687.	0.9	16



#	ARTICLE	IF	CITATIONS
133	Continuous Infusion of Time-dependent Antibiotics. <i>Clinical Pulmonary Medicine</i> , 2008, 15, 167-172.	0.3	1
134	Meropenem Pharmacokinetics, Pharmacodynamics, and Monte Carlo Simulation in the Neonate. <i>Pediatric Infectious Disease Journal</i> , 2008, 27, 794-799.	2.0	79
135	Enhanced and earlier detection of bacteremia and fungemia by multiplex polymerase chain reaction: How much enhanced, how much earlier, and at what cost?*. <i>Critical Care Medicine</i> , 2008, 36, 1660-1661.	0.9	11
136	Continuous regional arterial infusion therapy with biapenem and nafamostat mesilate for severe acute pancreatitis. <i>Suizo</i> , 2008, 23, 578-586.	0.1	2
137	Pharmacokinetics and Pharmacodynamics of Antibiotics : General Concepts and Recent Advances. <i>Infection and Chemotherapy</i> , 2008, 40, 140.	2.3	2
138	Vancomycin Continuous Infusion as Prophylaxis for Vascular Surgery. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 786-788.	2.0	5
139	Rationale for Revised Penicillin Susceptibility Breakpoints versus <i>Streptococcus pneumoniae</i> : Coping with Antimicrobial Susceptibility in an Era of Resistance. <i>Clinical Infectious Diseases</i> , 2009, 48, 1596-1600.	5.8	163
140	Resurgence of <i>Pseudomonas</i> Endocarditis in Detroit, 2006-2008. <i>Medicine (United States)</i> , 2009, 88, 294-301.	1.0	53
141	New Semiphysiological Absorption Model To Assess the Pharmacodynamic Profile of Cefuroxime Axetil Using Nonparametric and Parametric Population Pharmacokinetics. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3462-3471.	3.2	19
142	Mechanism and implication of cephalosporin penetration into oropharyngeal mucosa. <i>Journal of Infection and Chemotherapy</i> , 2009, 15, 70-74.	1.7	8
143	Effect of various estimates of renal function on prediction of vancomycin concentration by the population mean and Bayesian methods. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2009, 34, 465-472.	1.5	11
144	Antibiotics for Gram-Positive Bacterial Infections: Vancomycin, Teicoplanin, Quinupristin/Dalfopristin, Oxazolidinones, Daptomycin, Dalbavancin, and Telavancin. <i>Infectious Disease Clinics of North America</i> , 2009, 23, 965-982.	5.1	43
145	Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 65, 130-141.	1.8	17
147	Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 555-560.	2.5	55
148	Epidemiology, Prevention and Management of Ventriculoperitoneal Shunt Infections in Children. <i>Pediatric Neurosurgery</i> , 2009, 45, 325-336.	0.7	113
149	Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. <i>American Journal of Health-System Pharmacy</i> , 2009, 66, 82-98.	1.0	1,502
150	Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a Murine Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1314-1319.	3.2	185
151	Antistaphylococcal Agents. <i>Infectious Disease Clinics of North America</i> , 2009, 23, 99-131.	5.1	9

#	ARTICLE	IF	CITATIONS
152	Pharmacokinetics and Pharmacodynamics of Antibacterial Agents. Infectious Disease Clinics of North America, 2009, 23, 791-815.	5.1	387
153	Pharmacokinetic issues for antibiotics in the critically ill patient. Critical Care Medicine, 2009, 37, 840-851.	0.9	755
154	The jury is still out on continuous infusion of $\beta$ -lactam antibiotics in intensive care patients*. Critical Care Medicine, 2009, 37, 2137-2138.	0.9	8
155	Optimizing Antibiotic Use in the Intensive Care Unit. Clinical Pulmonary Medicine, 2010, 17, 162-169.	0.3	1
156	Pharmacokinetics, Pharmacodynamics, and Monte Carlo Simulation. Pediatric Infectious Disease Journal, 2010, 29, 1043-1046.	2.0	42
157	Vancomycin, unbeatable for methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia? Really?*. Critical Care Medicine, 2010, 38, 1910-1912.	0.9	4
158	Nosocomial methicillin-resistant staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - comparison of pharmacology and clinical efficacy. European Journal of Medical Research, 2010, 15, 507.	2.2	44
159	Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics. Journal of Pharmaceutical Sciences, 2010, 99, 1107-1122.	3.3	267
160	Pharmacokinetic/Pharmacodynamic Investigation of Colistin against <i>Pseudomonas aeruginosa</i> Using an <i>In Vitro</i> Model. Antimicrobial Agents and Chemotherapy, 2010, 54, 3783-3789.	3.2	150
161	Pharmacokinetic-Pharmacodynamic Assessment of Faropenem in a Lethal Murine <i>Bacillus anthracis</i> Inhalation Postexposure Prophylaxis Model. Antimicrobial Agents and Chemotherapy, 2010, 54, 1678-1683.	3.2	11
162	Generic Vancomycin Products Fail <i>In Vivo</i> despite Being Pharmaceutical Equivalents of the Innovator. Antimicrobial Agents and Chemotherapy, 2010, 54, 3271-3279.	3.2	88
163	<i>In Vivo</i> Efficacy of Simulated Human Dosing Regimens of Prolonged-Infusion Doripenem against Carbapenemase-Producing <i>Klebsiella pneumoniae</i> . Antimicrobial Agents and Chemotherapy, 2010, 54, 4112-4115.	3.2	50
164	Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?. Journal of Antimicrobial Chemotherapy, 2010, 65, 2141-2148.	3.0	154
165	<i>In Vivo</i> Pharmacodynamics of New Lipopeptide MX-2401. Antimicrobial Agents and Chemotherapy, 2010, 54, 5092-5098.	3.2	21
166	Optimal Antibiotic Therapy in the Management of the Lung of the Critically Ill. Current Respiratory Medicine Reviews, 2010, 6, 253-263.	0.2	0
167	Intra- and Extracellular Activities of Dicloxacillin against <i>Staphylococcus aureus</i> <i>In Vivo</i> and <i>In Vitro</i> . Antimicrobial Agents and Chemotherapy, 2010, 54, 2391-2400.	3.2	21
169	In vivo development of antimicrobial resistance in <i>Pseudomonas aeruginosa</i> strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. International Journal of Antimicrobial Agents, 2010, 36, 513-522.	2.5	72
170	Pharmacokinetic/pharmacodynamic (PK/PD) considerations in the management of Gram-positive bacteraemia. International Journal of Antimicrobial Agents, 2010, 36, S33-S39.	2.5	14

#	ARTICLE	IF	CITATIONS
171	Augmented Renal Clearance. Clinical Pharmacokinetics, 2010, 49, 1-16.	3.5	313
172	The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant <i>Staphylococcus aureus</i> : vancomycin and linezolid. Current Medical Research and Opinion, 2010, 26, 571-588.	1.9	110
173	Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections. Expert Review of Anti-Infective Therapy, 2010, 8, 95-106.	4.4	67
174	Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine. Expert Opinion on Pharmacotherapy, 2010, 11, 1373-1385.	1.8	17
175	Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of $\beta$ -lactams. Critical Care, 2011, 15, R206.	5.8	316
176	Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia. International Journal of Antimicrobial Agents, 2011, 38, 231-236.	2.5	37
177	Antibiotic policy. International Journal of Antimicrobial Agents, 2011, 38, 11-20.	2.5	56
178	Antimicrobial Pharmacokinetic and Pharmacodynamic Issues in the Critically Ill with Severe Sepsis and Septic Shock. Critical Care Clinics, 2011, 27, 19-34.	2.6	118
179	Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant <i>Acinetobacter</i> ?. Annals of Pharmacotherapy, 2011, 45, 229-240.	1.9	13
180	Antibiotics for Gram-Positive Bacterial Infection: Vancomycin, Teicoplanin, Quinupristin/Dalfopristin, Oxazolidinones, Daptomycin, Telavancin, and Ceftaroline. Medical Clinics of North America, 2011, 95, 723-742.	2.5	11
181	The Medicinal Chemistry of Tuberculosis Chemotherapy. Topics in Medicinal Chemistry, 2011, , 47-124.	0.8	17
182	Ceftaroline Fosamil: A Novel Broad-Spectrum Cephalosporin with Activity Against Methicillin-Resistant <i>Staphylococcus aureus</i> . Annals of Pharmacotherapy, 2011, 45, 1384-1398.	1.9	28
183	Controlling Drug Release in Oral Product Development Programs: An Industrial Perspective. , 2011, , 49-69.		3
184	Sepsis: new strategies for management. Critical Care, 2011, 15, 306.	5.8	0
185	Cefuroxime Pharmacokinetics in Pediatric Cardiovascular Surgery Patients Undergoing Cardiopulmonary Bypass. Journal of Cardiothoracic and Vascular Anesthesia, 2011, 25, 425-430.	1.3	22
186	Successful Utilization of High-Flux Hemodialysis for Treatment of Vancomycin Toxicity in a Child. Case Reports in Pediatrics, 2011, 2011, 1-4.	0.4	11
187	Teicoplanin Dosing Strategy for Treatment of <i>Staphylococcus aureus</i> in Korean Patients with Neutropenic Fever. Yonsei Medical Journal, 2011, 52, 616.	2.2	16
188	Clinical Pharmacology of Anti-Infective Drugs. , 2011, , 1160-1211.		7

#	ARTICLE	IF	CITATIONS
189	Triple Therapy with Ecabet Sodium, Amoxicillin and Lansoprazole for 2 Weeks as the Rescue Regimen for H. pylori Infection. Internal Medicine, 2011, 50, 369-374.	0.7	14
190	Novel gastroretentive controlled-release drug delivery system for amoxicillin therapy in veterinary medicine. Journal of Veterinary Pharmacology and Therapeutics, 2011, 34, 487-493.	1.3	7
191	Pharmacokinetics of ceftiofur crystalline-free acid sterile suspension in the equine. Journal of Veterinary Pharmacology and Therapeutics, 2011, 34, 476-481.	1.3	35
193	WSES consensus conference: Guidelines for first-line management of intra-abdominal infections. World Journal of Emergency Surgery, 2011, 6, 2.	5.0	57
194	Vancomycin dosing and monitoring 2 years after the guidelines. Expert Review of Anti-Infective Therapy, 2011, 9, 657-667.	4.4	20
195	Refining Vancomycin Protein Binding Estimates: Identification of Clinical Factors That Influence Protein Binding. Antimicrobial Agents and Chemotherapy, 2011, 55, 4277-4282.	3.2	69
196	Vancomycin: We Can't Get There From Here. Clinical Infectious Diseases, 2011, 52, 969-974.	5.8	214
197	Relationship between Vancomycin Trough Concentrations and Nephrotoxicity: a Prospective Multicenter Trial. Antimicrobial Agents and Chemotherapy, 2011, 55, 5475-5479.	3.2	213
198	Improving antibiotic dosing in special situations in the ICU. Current Opinion in Critical Care, 2012, 18, 460-471.	3.2	86
199	Is Peak Concentration Needed in Therapeutic Drug Monitoring of Vancomycin? A Pharmacokinetic-Pharmacodynamic Analysis in Patients with Methicillin-Resistant <i>Staphylococcus aureus</i> and <i>Pneumonia</i>. Chemotherapy, 2012, 58, 308-312.	1.6	100
200	Pharmacodynamics of TD-1792, a Novel Glycopeptide-Cephalosporin Heterodimer Antibiotic Used against Gram-Positive Bacteria, in a Neutropenic Murine Thigh Model. Antimicrobial Agents and Chemotherapy, 2012, 56, 1578-1583.	3.2	25
201	Evaluation of Once-Daily Vancomycin against Methicillin-Resistant <i>Staphylococcus aureus</i> in a Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2012, 56, 682-686.	3.2	33
202	A Simplified Oral Flucloxacillin Absorption Test for Patients Requiring Long-Term Treatment. Therapeutic Drug Monitoring, 2012, 34, 356-358.	2.0	8
203	Risk factors for 30-day mortality in adult patients with pneumococcal bacteraemia, and the impact of antimicrobial resistance on clinical outcomes. Epidemiology and Infection, 2012, 140, 1267-1276.	2.1	15
204	Applications of Pharmacokinetic and Pharmacodynamic Principles to Optimize Drug Dosage Selection. , 2012, , 175-196.		0
205	Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Critical Care, 2012, 16, R113.	5.8	119
206	In vitro synergy, pharmacodynamics, and postantibiotic effect of 11 antimicrobial agents against <i>Rhodococcus equi</i>. Veterinary Microbiology, 2012, 160, 207-213.	1.9	51
207	The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clinical Microbiology and Infection, 2012, 18, E37-E45.	6.0	232

#	ARTICLE	IF	CITATIONS
208	Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia. <i>International Journal of Antimicrobial Agents</i> , 2012, 40, 434-439.	2.5	24
209	Continuous beta-lactam infusion in critically ill patients: the clinical evidence. <i>Annals of Intensive Care</i> , 2012, 2, 37.	4.6	85
210	Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin?. <i>Annals of Intensive Care</i> , 2012, 2, 22.	4.6	41
211	Reduced vancomycin susceptibility among clinical <i>Staphylococcus aureus</i> isolates (the MIC Creep™): implications for therapy. <i>F1000 Medicine Reports</i> , 2012, 4, 4.	2.9	90
212	Importance of High Creatinine Clearance for Antibacterial Treatment in Sepsis. , 2012, , 171-197.		0
213	Vancomycin AUC <sub>24</sub> /MIC Ratio in Patients with Complicated Bacteremia and Infective Endocarditis Due to Methicillin-Resistant <i>Staphylococcus aureus</i> and Its Association with Attributable Mortality during Hospitalization. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 634-638.	3.2	99
214	Loading Dose Required to Achieve Rapid Therapeutic Teicoplanin Trough Plasma Concentration in Patients with Multidrug-Resistant <i>Gram-Positive</i> Infections. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012, 110, 416-420.	2.5	15
215	β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: A structured review. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2012, 39, 489-496.	1.9	74
216	A survey of beta-lactam antibiotics and vancomycin dosing strategies in intensive care units and general wards in Belgian hospitals. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 763-768.	2.9	39
218	Prescribing Habits of Vancomycin in the Emergency Department: Are We Dosing Appropriately?. <i>Journal of Emergency Medicine</i> , 2013, 44, 979-984.	0.7	10
219	When is Protein Binding Important?*. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3458-3467.	3.3	64
220	<i>In Vitro</i> and <i>In Vivo</i> Efficacy of β-Lactams against Replicating and Slowly Growing/Nonreplicating <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2506-2510.	3.2	65
221	β-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 162-166.	2.5	65
222	Ticarcillin, une alternative aux carbapénèmes pour traiter les infections bactériennes résistantes aux C3G?. <i>Journal Des Anti-infectieux</i> , 2013, 15, 60-70.	0.1	3
223	Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 439-446.	2.5	40
224	Synthetic amphiphiles as therapeutic antibacterials: lessons on bactericidal efficacy and cytotoxicity and potential application as an adjuvant in antimicrobial chemotherapy. <i>Journal of Materials Chemistry B</i> , 2013, 1, 2612.	5.8	17
225	Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 900-906.	3.0	105
226	Inoculum Effects of Ceftobiprole, Daptomycin, Linezolid, and Vancomycin with <i>Staphylococcus aureus</i> and <i>Streptococcus pneumoniae</i> at Inocula of 10 <sup>5</sup> and 10 <sup>7</sup> CFU Injected into Opposite Thighs of Neutropenic Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1434-1441.	3.2	48

#	ARTICLE	IF	CITATIONS
227	Pharmacodynamic Variability beyond That Explained by MICs. Antimicrobial Agents and Chemotherapy, 2013, 57, 1730-1735.	3.2	12
228	Defining Antibiotic Dosing in Lung Infections. Clinical Pulmonary Medicine, 2013, 20, 121-128.	0.3	18
229	Risk Factors for a Low Linezolid Trough Plasma Concentration in Acute Infections. Antimicrobial Agents and Chemotherapy, 2013, 57, 1913-1917.	3.2	53
230	Human Simulated Studies of Aztreonam and Aztreonam-Avibactam To Evaluate Activity against Challenging Gram-Negative Organisms, Including Metallo- $\beta$ -Lactamase Producers. Antimicrobial Agents and Chemotherapy, 2013, 57, 3299-3306.	3.2	92
231	Reply to "Breakthrough Bacteremia by Linezolid-Susceptible Enterococcus faecalis under Linezolid Treatment in a Severe Polytrauma Patient". Antimicrobial Agents and Chemotherapy, 2013, 57, 6413-6414.	3.2	0
232	Vancomycin AUC/MIC Ratio and 30-Day Mortality in Patients with Staphylococcus aureus Bacteremia. Antimicrobial Agents and Chemotherapy, 2013, 57, 1654-1663.	3.2	176
233	In Vivo Activities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum $\beta$ -Lactamases, in the Thighs of Neutropenic Mice. Antimicrobial Agents and Chemotherapy, 2013, 57, 1577-1582.	3.2	118
234	High Rate of Per Oral Mecillinam Treatment Failure in Community-Acquired Urinary Tract Infections Caused by ESBL-Producing Escherichia coli. PLoS ONE, 2014, 9, e85889.	2.5	55
237	Exposure to Ceftobiprole Is Associated with Microbiological Eradication and Clinical Cure in Patients with Nosocomial Pneumonia. Antimicrobial Agents and Chemotherapy, 2014, 58, 2512-2519.	3.2	43
238	Activities of Ceftazidime and Avibactam against $\beta$ -Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2014, 58, 3366-3372.	3.2	74
239	The pathway-specific regulatory genes, <i>tei15*</i> and <i>tei16*</i> , are the master switches of teicoplanin production in Actinoplanes teichomyceticus. Applied Microbiology and Biotechnology, 2014, 98, 9295-9309.	3.6	36
240	Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 487-493.	2.8	32
241	Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy. Journal of Clinical Pharmacology, 2014, 54, 258-266.	2.0	42
242	Low or High Doses of Cefquinome Targeting Low or High Bacterial Inocula Cure Klebsiella pneumoniae Lung Infections but Differentially Impact the Levels of Antibiotic Resistance in Fecal Flora. Antimicrobial Agents and Chemotherapy, 2014, 58, 1744-1748.	3.2	37
243	Pharmacodynamics of Cefquinome in a Neutropenic Mouse Thigh Model of Staphylococcus aureus Infection. Antimicrobial Agents and Chemotherapy, 2014, 58, 3008-3012.	3.2	41
244	Glycopeptides. , 2014, , 279-322.		0
245	Introduction to Pharmacodynamics. , 2014, , 3-22.		2
247	Population Pharmacokinetic-Pharmacodynamic (PK/PD) Modeling of Anti-infective Agents and Its Applications to Individualized Therapy. , 2014, , 113-134.		0



#	ARTICLE	IF	CITATIONS
248	<i>In Vivo</i> Efficacy of Human Simulated Regimens of Carbapenems and Comparator Agents against NDM-1-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2014, 58, 1671-1677.	3.2	32
249	Impact of Renal Function on the Pharmacokinetics and Safety of Ceftolozane-Tazobactam. Antimicrobial Agents and Chemotherapy, 2014, 58, 2249-2255.	3.2	67
250	Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against methicillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches. International Journal of Antimicrobial Agents, 2014, 43, 60-67.	2.5	19
251	Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology. Advanced Drug Delivery Reviews, 2014, 73, 127-139.	13.7	33
252	Evaluation of Imipenem for Prophylaxis and Therapy of Yersinia pestis Delivered by Aerosol in a Mouse Model of Pneumonic Plague. Antimicrobial Agents and Chemotherapy, 2014, 58, 3276-3284.	3.2	11
253	Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infectious Diseases, The, 2014, 14, 498-509.	9.1	745
254	Vancomycin Exposure in Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: How Much Is Enough?. Clinical Infectious Diseases, 2014, 59, 666-675.	5.8	139
255	Editorial Commentary: Are Blood Concentrations Enough for Establishing Pharmacokinetic/Pharmacodynamic Relationships?. Clinical Infectious Diseases, 2014, 58, 1084-1085.	5.8	9
256	<i>In Vivo</i> Activity of Cefquinome against Escherichia coli in the Thighs of Neutropenic Mice. Antimicrobial Agents and Chemotherapy, 2014, 58, 5943-5946.	3.2	19
257	A Retrospective Review of the Clinical Experience of Linezolid with or Without Rifampicin in Prosthetic Joint Infections Treated with Debridement and Implant Retention. Infectious Diseases and Therapy, 2014, 3, 235-243.	4.0	38
258	Amphiphile-mediated enhanced antibiotic efficacy and development of a payload nanocarrier for effective killing of pathogenic bacteria. Journal of Materials Chemistry B, 2014, 2, 5818.	5.8	20
259	Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa. Bioorganic and Medicinal Chemistry, 2014, 22, 5392-5409.	3.0	26
260	Biocompatible Nanocarrier Fortified with a Dipyrindinium-Based Amphiphile for Eradication of Biofilm. ACS Applied Materials & Interfaces, 2014, 6, 16384-16394.	8.0	54
261	Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections. Expert Review of Anti-Infective Therapy, 2014, 12, 1371-1388.	4.4	12
262	Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: A narrative and systematic review. Journal of Critical Care, 2014, 29, 1089-1095.	2.2	28
263	Innovative approaches to optimizing the delivery of vancomycin in individual patients. Advanced Drug Delivery Reviews, 2014, 77, 50-57.	13.7	215
264	Pharmacokinetics of an Extended 4-hour Infusion of Piperacillin-Tazobactam in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy. Pharmacotherapy, 2015, 35, 600-607.	2.6	18
265	Gap Analysis of Pharmacokinetics and Pharmacodynamics in Burn Patients. Journal of Burn Care and Research, 2015, 36, e194-e211.	0.4	24



#	ARTICLE	IF	CITATIONS
266	Cephalosporins. , 2015, , 278-292.e4.		18
267	Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem during the Early Phase of Severe Sepsis and Septic Shock in Critically Ill Patients in Intensive Care Units. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2995-3001.	3.2	66
268	Pharmacokinetics/pharmacodynamics of a $\beta$ -lactam and $\beta$ -lactamase inhibitor combination: a novel approach for aztreonam/avibactam. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2618-2626.	3.0	70
269	Antibiotic Tissue Penetration in Diabetic Foot Infections. <i>Journal of the American Podiatric Medical Association</i> , 2015, 105, 520-531.	0.3	10
270	Activity of temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam against carbapenem-non-susceptible Enterobacteriaceae without carbapenemase production. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 2429-2437.	2.9	13
271	Thrice-weekly temocillin administered after each dialysis session is appropriate for the treatment of serious Gram-negative infections in haemodialysis patients. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 660-665.	2.5	5
272	Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration. <i>Intensive Care Medicine</i> , 2015, 41, 103-110.	8.2	37
273	Concentration-response studies and modelling of the pharmacodynamics of linezolid: <i>Staphylococcus aureus</i> versus <i>Enterococcus faecium</i> . <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 54-60.	2.5	11
274	How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 82, 92-103.	1.8	68
275	Pharmacodynamic Evaluation of the Activities of Six Parenteral Vancomycin Products Available in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 622-632.	3.2	10
276	<i>In vitro</i> assessment of chloramphenicol and florfenicol as second-line antimicrobial agents in dogs. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2015, 38, 443-450.	1.3	12
277	Validation of a HPLC-MS/MS assay for the determination of total and unbound concentration of temocillin in human serum. <i>Clinical Biochemistry</i> , 2015, 48, 542-545.	1.9	12
278	Pharmacokinetics of cefquinome in tilapia ( <i>Oreochromis niloticus</i> ) after a single intramuscular or intraperitoneal administration. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2015, 38, 601-605.	1.3	11
279	Antimicrobial dosing in critically ill patients with sepsis-induced acute kidney injury. <i>Indian Journal of Critical Care Medicine</i> , 2015, 19, 99-108.	0.9	16
280	Pharmacokinetics of Vancomycin in Extremely Obese Patients with Suspected or Confirmed <i>Staphylococcus aureus</i> Infections. <i>Pharmacotherapy</i> , 2015, 35, 127-139.	2.6	79
281	Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1261-1273.	4.1	8
282	Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 1265-1278.	4.4	19
283	Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients. <i>Burns</i> , 2015, 41, 956-968.	1.9	47

#	ARTICLE	IF	CITATIONS
284	Association between Vancomycin Day 1 Exposure Profile and Outcomes among Patients with Methicillin-Resistant <i>Staphylococcus aureus</i> Infective Endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2978-2985.	3.2	68
285	Ceftazidime+avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 691-707.	3.1	25
286	Response of a clinical <i>Escherichia coli</i> strain to repeated cefquinome exposure in a piglet tissue-cage model. <i>BMC Veterinary Research</i> , 2015, 11, 169.	1.9	11
287	Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in <i>Pseudomonas aeruginosa</i> : Assessing the Risk for Resistance and Attenuated Efficacy. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7743-7752.	3.2	64
288	Cefazolin and linezolid penetration into sternal cancellous bone during coronary artery bypass grafting. <i>European Journal of Cardio-thoracic Surgery</i> , 2015, 48, 758-764.	1.4	13
289	A zinc complex of a neutral pyridine-based amphiphile: a highly efficient and potentially therapeutic bactericidal material. <i>Journal of Materials Chemistry B</i> , 2015, 3, 7068-7078.	5.8	11
290	Pharmacokinetics of doripenem during high volume hemodiafiltration in patients with septic shock. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 438-446.	2.0	6
291	Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 891-898.	3.0	71
292	A retrospective analysis to estimate target trough concentration of vancomycin for febrile neutropenia in patients with hematological malignancy. <i>Clinica Chimica Acta</i> , 2015, 440, 183-187.	1.1	18
293	An Optimized Mouse Thigh Infection Model for Enterococci and Its Impact on Antimicrobial Pharmacodynamics. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 233-238.	3.2	9
294	Teicoplanin therapy for MRSA bacteraemia: a retrospective study emphasizing the importance of maintenance dosing in improving clinical outcomes. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 257-263.	3.0	26
295	Multilayered Controlled Released Topical Patch Containing Tetracycline for Wound Dressing. <i>Journal of in Silico &amp; in Vitro Pharmacology</i> , 2016, 02, .	0.2	12
296	Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections. <i>Clinical Pharmacology: Advances and Applications</i> , 2016, 8, 15.	1.2	24
297	Association between the AUC <sub>0-24</sub> /MIC Ratio of Vancomycin and Its Clinical Effectiveness: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0146224.	2.5	92
298	Renal Function Descriptors in Neonates: Which Creatinine-Based Formula Best Describes Vancomycin Clearance?. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 528-540.	2.0	8
299	Serum Î²-lactam concentrations in critically ill patients with cirrhosis: a matched case-control study. <i>Liver International</i> , 2016, 36, 1002-1010.	3.9	12
300	Pharmacodynamic Considerations in Critically Ill Patients. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 537-560.	0.2	1
301	Therapeutic drug monitoring of anti-infective agents in critically ill patients. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 961-979.	3.1	98

#	ARTICLE	IF	CITATIONS
302	Preparing and administering injectable antibiotics: How to avoid playing God. <i>MÃ©decine Et Maladies Infectieuses</i> , 2016, 46, 242-268.	5.0	35
303	ExÂvivo pharmacokinetic/pharmacodynamic relationship of valnemulin against <i>Clostridium perfringens</i> in plasma, the small intestinal and caecal contents of rabbits. <i>Anaerobe</i> , 2016, 39, 150-157.	2.1	10
305	Vancomycin Pharmacodynamics: Optimal vs. Controversial. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 261-284.	0.2	0
306	A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6626-6634.	3.2	26
307	Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant <i>Acinetobacter baumannii</i> . <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 719-724.	2.5	14
308	Methodologies for Protein Binding Determination in Anti-infective Agents. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 109-125.	0.2	0
309	Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 307-315.	2.0	35
310	Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 909-935.	2.0	61
311	Antibiotic Dosing During Continuous Renal Replacement Therapy (CRRT). , 2016, , 1-33.		0
312	Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing. <i>Clinical Therapeutics</i> , 2016, 38, 1930-1947.	2.5	112
313	Flucloxacillin does not achieve therapeutic cerebrospinal fluid levels against meticillin-sensitive <i>Staphylococcus aureus</i> in adults: A case report and review of the literature. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 229-231.	2.5	7
314	Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1013-1021.	3.2	53
315	Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an <i>In Vitro</i> Pharmacokinetic Model of Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 515-521.	3.2	18
316	Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 368-375.	3.2	87
317	Optimizing the Clinical Use of Vancomycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2601-2609.	3.2	182
318	Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 464-470.	3.0	36
319	Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 196-207.	3.0	129
320	Population pharmacokinetics of teicoplanin and attainment ofÂpharmacokinetic/pharmacodynamic targets in adult patients withÂhaematological malignancy. <i>Clinical Microbiology and Infection</i> , 2017, 23, 674.e7-674.e13.	6.0	29

#	ARTICLE	IF	CITATIONS
322	Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	22
323	Optimal teicoplanin dosage regimens for methicillin-resistant <i>Staphylococcus aureus</i> infections in endocarditis patients and renal failure patients. <i>Journal of Chemotherapy</i> , 2017, 29, 358-364.	1.5	3
324	Optimizing $\beta$ -lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 677-688.	4.4	77
325	Variability in Trough Total and Unbound Teicoplanin Concentrations and Achievement of Therapeutic Drug Monitoring Targets in Adult Patients with Hematological Malignancy. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	21
326	Delayed Second Dose Antibiotics for Patients Admitted From the Emergency Department With Sepsis. <i>Critical Care Medicine</i> , 2017, 45, 956-965.	0.9	41
327	Conventional Versus Prolonged Infusion of Meropenem in Neonates With Gram-negative Late-onset Sepsis. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 358-363.	2.0	52
328	Impact of $\beta$ -lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 589-594.	2.5	52
329	Pharmacokinetic and pharmacodynamic characterization of ceftiofur crystalline free acid following subcutaneous administration in domestic goats. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2017, 40, 429-438.	1.3	9
330	Vancomycin therapy in secondary care; investigating factors that impact therapeutic target attainment. <i>Journal of Infection</i> , 2017, 74, 320-324.	3.3	1
331	Ceftaroline efficacy against high-MIC clinical <i>Staphylococcus aureus</i> isolates in an in vitro hollow-fibre infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2796-2803.	3.0	18
332	Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2804-2812.	3.0	30
333	Pharmacodynamics of Cefepime Combined with Tazobactam against Clinically Relevant Enterobacteriaceae in a Neutropenic Mouse Thigh Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	12
334	Ex Vivo Model to Decipher the Impact of Extracorporeal Membrane Oxygenation on Beta-lactam Degradation Kinetics. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 180-184.	2.0	28
335	Mechanisms of Action. , 2017, , 1162-1180.e1.		30
337	Activity of cefquinome against extended-spectrum $\beta$ -lactamase-producing <i>Klebsiella pneumoniae</i> in neutropenic mouse thigh model. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2017, 40, 392-397.	1.3	4
338	Determining optimal dosing regimen of oral administration of dicloxacillin using Monte Carlo simulation. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1951-1956.	4.3	4
339	Optimizing Single-Drug Antibacterial and Antifungal Therapy. , 2017, , 157-179.		1
340	Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate <i>Staphylococcus aureus</i> (hVISA) by Etest <sup>®</sup> macromethod among patients with MRSA bloodstream infections: a pilot study. <i>BMC Infectious Diseases</i> , 2017, 17, 534.	2.9	7

#	ARTICLE	IF	CITATIONS
341	Dosing of Ertapenem in an Extreme Obesity: A Case Report of 250â€%kg Patient. Case Reports in Critical Care, 2017, 2017, 1-3.	0.4	0
342	Avibactam Pharmacokinetic/Pharmacodynamic Targets. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	62
344	Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice. European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43, 259-268.	1.6	33
345	Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae â€“ Identification of LYS228. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 748-755.	2.2	48
346	Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis: A Randomized Controlled Trial. Digestion, 2018, 97, 163-169.	2.3	4
347	Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy. Journal of Antimicrobial Chemotherapy, 2018, 73, 995-1003.	3.0	34
348	Therapeutic Drug Monitoring of Teicoplanin in Haematological Malignancy Patients with Febrile Neutropenia and Optimizing Dosage Regimens. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 594-601.	2.5	7
349	Temocillin dosing in haemodialysis patients based on population pharmacokinetics of total and unbound concentrations and Monte Carlo simulations. Journal of Antimicrobial Chemotherapy, 2018, 73, 1630-1638.	3.0	4
350	Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants. European Journal of Clinical Pharmacology, 2018, 74, 921-930.	1.9	41
351	Individualising Therapy to Minimize Bacterial Multidrug Resistance. Drugs, 2018, 78, 621-641.	10.9	48
352	Pharmacokinetic/pharmacodynamic parameters for treatment optimization of infection due to antibiotic resistant bacteria: a summary for practical purposes in children and adults. Journal of Chemotherapy, 2018, 30, 65-81.	1.5	18
353	Pharmacokinetics and Pharmacodynamics of Temocillin. Clinical Pharmacokinetics, 2018, 57, 287-296.	3.5	42
354	Basic Pharmacokinetic Principles. , 2018, , 1-16.		1
355	Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?. Clinical Pharmacokinetics, 2018, 57, 439-454.	3.5	22
356	Physical and chemical stability of ceftaroline in an elastomeric infusion device. European Journal of Hospital Pharmacy, 2018, 25, e115-e119.	1.1	13
357	Ventriculoperitoneal shunt infection in Haji Adam Malik Hospital, Medan. IOP Conference Series: Earth and Environmental Science, 2018, 125, 012092.	0.3	0
358	Optimising drug dosing in patients receiving extracorporeal membrane oxygenation. Journal of Thoracic Disease, 2018, 10, S629-S641.	1.4	110
360	Ceftriaxone Absorption Enhancement for Noninvasive Administration as an Alternative to Injectable Solutions. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	5

#	ARTICLE	IF	CITATIONS
361	Pharmacokinetics and pharmacodynamics of the novel monobactam LYS228 in a neutropenic murine thigh model of infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 108-116.	3.0	6
362	Î²-Lactam Dosage Regimens in Septic Patients with Augmented Renal Clearance. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	49
363	Population pharmacokinetics and dosing optimization of cefthiamidine in children with hematologic infection. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 855-862.	4.3	4
364	Population pharmacokinetic analysis of linezolid in patients with different types of shock: Effect of platelet count. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 1786-1792.	1.8	3
365	Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2979-2983.	3.0	5
366	Determining therapeutic trough ranges for linezolid. <i>Saudi Pharmaceutical Journal</i> , 2019, 27, 1061-1063.	2.7	8
367	Antibiotic resistance genes identified in wastewater treatment plant systems – A review. <i>Science of the Total Environment</i> , 2019, 697, 134023.	8.0	396
368	The importance of dosing interval in limiting vancomycin AUC with trough monitoring. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 487-492.	1.0	5
369	Simultaneous Quantification of Nine Antimicrobials by LC-MS/MS for Therapeutic Drug Monitoring in Critically Ill Patients. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 29-37.	2.0	25
370	Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with <i>Pseudomonas aeruginosa</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 1457-1461.	2.9	33
371	Population Pharmacokinetic Modeling and Probability of Target Attainment Analyses in Asian Patients With Community-Acquired Pneumonia Treated With Ceftaroline Fosamil. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 682-694.	1.6	6
372	Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	8
373	Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	3.2	21
375	WCK 5222 (Cefepime-Zidebactam) Pharmacodynamic Target Analysis against Metallo-Î²-Lactamase-Producing Enterobacteriaceae in the Neutropenic Mouse Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	17
376	Optimizing the management of <i>Pseudomonas aeruginosa</i> infections with tools for the detection of resistance mechanisms and pharmacokinetic/pharmacodynamic (PK/PD) analysis. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed )</i> , 2019, 37, 623-625.	0.3	0
377	Antibiotics in Emergency General Surgery. , 2019, , 41-56.		0
378	Ceftaroline fosamil doses and breakpoints for <i>Staphylococcus aureus</i> in complicated skin and soft tissue infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 425-431.	3.0	31
379	Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment. <i>Journal of Critical Care</i> , 2019, 50, 69-76.	2.2	27



#	ARTICLE	IF	CITATIONS
380	Outpatient parenteral antimicrobial therapy and antibiotic stewardship: opponents or teammates?. <i>Infection</i> , 2019, 47, 169-181.	4.7	24
381	Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	26
382	Population Pharmacokinetics and Dosing Optimization of Amoxicillin in Neonates and Young Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	29
383	Augmented renal clearance in pediatric intensive care: are we undertreating our sickest patients?. <i>Pediatric Nephrology</i> , 2020, 35, 25-39.	1.7	53
384	Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of <i>Helicobacter pylori</i> . <i>Digestion</i> , 2020, 101, 743-751.	2.3	87
385	Therapeutic drug monitoring of antibiotics in critically ill patients. <i>Handbook of Analytical Separations</i> , 2020, 7, 169-183.	0.8	4
386	Dosage Regimens for Meropenem in Children with <i>Pseudomonas</i> Infections Do Not Meet Serum Concentration Targets. <i>Clinical and Translational Science</i> , 2020, 13, 301-308.	3.1	9
387	Selecting the dosage of ceftazidime-avibactam in the perfect storm of nosocomial pneumonia. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 349-361.	1.9	9
388	Pharmacokinetic variability of beta-lactams in critically ill patients: A narrative review. <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2020, 39, 87-109.	1.4	18
389	Preoperative Vancomycin Administration for Surgical Site Prophylaxis. <i>Anesthesia and Analgesia</i> , 2020, 130, 1435-1444.	2.2	0
390	Comparison of extended versus intermittent infusion of antipseudomonal beta-lactams for the treatment of critically ill patients with respiratory infections: A systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2020, 98, 41-50.	3.3	8
391	What is the optimal loading dose of broad-spectrum $\beta$ -lactam antibiotics in septic patients? Results from pharmacokinetic simulation modelling. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106113.	2.5	17
392	Early therapeutic monitoring of $\beta$ -lactams and associated therapy outcomes in critically ill patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3644-3651.	3.0	44
393	Population Pharmacokinetics of Teicoplanin in Preterm and Term Neonates: Is It Time for a New Dosing Regimen?. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	8
394	Optimizing Antibiotic Treatment Strategies for Neonates and Children: Does Implementing Extended or Prolonged Infusion Provide any Advantage?. <i>Antibiotics</i> , 2020, 9, 329.	3.7	11
395	Therapeutic monitoring of vancomycin for serious methicillin-resistant <i>Staphylococcus aureus</i> infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 835-864.	1.0	640
396	Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	25
397	Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 µg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days. <i>BMC Pharmacology &amp; Toxicology</i> , 2020, 21, 50.	2.4	21



#	ARTICLE	IF	CITATIONS
398	Should Therapeutic Monitoring of Vancomycin Based on Area under the Curve Become Standard Practice for Patients with Confirmed or Suspected Methicillin-Resistant <i>Staphylococcus aureus</i> Infection?. Canadian Journal of Hospital Pharmacy, 2020, 73, .	0.1	2
399	Teicoplanin and therapeutic drug monitoring: An update for optimal use in different patient populations. Journal of Infection and Chemotherapy, 2020, 26, 900-907.	1.7	19
400	Impact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective. International Journal of Infectious Diseases, 2020, 93, 329-338.	3.3	36
401	Use of Monte Carlo simulation to optimize antibiotic selection for bloodstream infections caused by Enterobacteriaceae in Shandong Province, China. Diagnostic Microbiology and Infectious Disease, 2020, 97, 115039.	1.8	1
402	Population pharmacokinetics and dosing optimization of azlocillin in neonates with early-onset sepsis: a real-world study. Journal of Antimicrobial Chemotherapy, 2021, 76, 699-709.	3.0	11
403	The Pharmacodynamic-Toxicodynamic Relationship of AUC and $C_{max}$ in Vancomycin-Induced Kidney Injury in an Animal Model. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	13
404	Prolonged infusion of linezolid is associated with improved pharmacokinetic/pharmacodynamic (PK/PD) profiles in patients with external ventricular drains. European Journal of Clinical Pharmacology, 2021, 77, 79-86.	1.9	5
405	How to optimize administration of cefoxitin for the treatment of extended spectrum producing Enterobacteriaceae-related infection?. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1393-1397.	2.9	3
406	Wastewater Treatment Plants as emerging source of antibiotic resistance. , 2021, , 239-269.		4
407	Ceftazidime-Avibactam Use for <i>Klebsiella pneumoniae</i> Carbapenemase-Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study. Clinical Infectious Diseases, 2021, 73, 1664-1676.	5.8	130
408	Optimal trough concentration of teicoplanin for the treatment of methicillin-resistant <i>Staphylococcus aureus</i> infection: A systematic review and meta-analysis. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 622-632.	1.5	13
409	Population Pharmacokinetics of Piperacillin in Non-Critically Ill Patients with Bacteremia Caused by Enterobacteriaceae. Antibiotics, 2021, 10, 348.	3.7	3
410	AUCs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics. Journal of Antimicrobial Chemotherapy, 2021, 76, 2237-2251.	3.0	15
411	Pharmacokinetic/Pharmacodynamic Dosage Individualization of Suppressive Beta-Lactam Therapy Administered by Subcutaneous Route in Patients With Prosthetic Joint Infection. Frontiers in Medicine, 2021, 8, 583086.	2.6	7
412	Should Therapeutic Drug Monitoring Based on the Vancomycin Area Under the Concentration-Time Curve Be Standard for Serious Methicillin-Resistant <i>Staphylococcus aureus</i> Infections? No. Clinical Infectious Diseases, 2021, 72, 1502-1506.	5.8	14
413	Individualized Vancomycin Dosing with Therapeutic Drug Monitoring and Pharmacokinetic Consultation Service: A Large-Scale Retrospective Observational Study. Drug Design, Development and Therapy, 2021, Volume 15, 423-440.	4.3	5
414	Pharmacokinetic/pharmacodynamic evaluation of teicoplanin against <i>Staphylococcus aureus</i> in a murine thigh infection model. Journal of Global Antimicrobial Resistance, 2021, 24, 83-87.	2.2	8
415	Comment on: The case for "conservative pharmacotherapy". Journal of Antimicrobial Chemotherapy, 2021, 76, 1951-1952.	3.0	1

#	ARTICLE	IF	CITATIONS
416	Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens. Expert Review of Clinical Pharmacology, 2021, 14, 777-791.	3.1	4
417	The case for “conservative pharmacotherapy” authors’ response. Journal of Antimicrobial Chemotherapy, 2021, 76, 1952-1953.	3.0	0
418	Cefepime Population Pharmacokinetics and Target Attainment in Critically Ill Patients on Continuous Renal Replacement Therapy. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	7
419	Quantification of persister formation of <i>Escherichia coli</i> leveraging electronic cell counting and semi-mechanistic pharmacokinetic/pharmacodynamic modelling. Journal of Antimicrobial Chemotherapy, 2021, 76, 2088-2096.	3.0	6
420	Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant <i>Escherichia coli</i> . Antibiotics, 2021, 10, 615.	3.7	4
421	Prevalence of Antibiotic Resistance Genes in Pharmaceutical Wastewaters. Water (Switzerland), 2021, 13, 1731.	2.7	3
422	Optimizing Antimicrobial Drug Dosing in Critically Ill Patients. Microorganisms, 2021, 9, 1401.	3.6	27
423	Optimizing antimicrobial use: challenges, advances and opportunities. Nature Reviews Microbiology, 2021, 19, 747-758.	28.6	51
424	Optimal Sampling Strategy and Threshold of Serum Vancomycin Concentration in Elderly Japanese Patients undergoing High-flux Hemodialysis. Therapeutic Drug Monitoring, 2021, Publish Ahead of Print, .	2.0	0
425	Individualized precision dosing approaches to optimize antimicrobial therapy in pediatric populations. Expert Review of Clinical Pharmacology, 2021, 14, 1383-1399.	3.1	8
426	Treatment of Native Valve Endocarditis: General Principles and Therapy for Specific Organisms. , 2006, , 121-183.		2
427	Treatment of Endocarditis. , 2016, , 181-280.		1
428	Mechanisms of Resistance in <i>Haemophilus influenzae</i> and <i>Moraxella catarrhalis</i> . , 2017, , 867-888.		3
429	Third World Diseases. Topics in Medicinal Chemistry, 2011, , .	0.8	2
430	Cephalosporins. , 2010, , 323-339.		3
433	Clinical Validation of Therapeutic Drug Monitoring of Imipenem in Spent Effluent in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Pilot Study. PLoS ONE, 2016, 11, e0153927.	2.5	10
434	Infection-stage adjusted dose of beta-lactams for parsimonious and efficient antibiotic treatments: A <i>Pasteurella multocida</i> experimental pneumonia in mice. PLoS ONE, 2017, 12, e0182863.	2.5	13
435	Pharmacodynamics of Antimicrobials: General Concepts and Applications. Infectious Disease and Therapy, 2007, , 1-20.	0.0	42

#	ARTICLE	IF	CITATIONS
436	A Pharmacokinetic and Pharmacodynamic Study on Intravenous Cefazedone Sodium in Patients with Community-acquired Pneumonia. Chinese Medical Journal, 2015, 128, 1160-1164.	2.3	1
437	Assessment of Susceptibility, Pharmacodynamics, and Therapeutic Response for Interpretation of Piperacillin-Tazobactam <i>in Vitro</i> Activity in the Treatment of <i>Pseudomonas aeruginosa</i> Infection. Open Journal of Medical Microbiology, 2012, 02, 101-109.	0.4	2
438	Vancomycin. Journal of the American Academy of Orthopaedic Surgeons, The, 2005, 13, 89-92.	2.5	14
439	Performance of Various Pharmacokinetic Parameters in Predicting Vancomycin Serum Concentrations. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2008, 34, 1-12.	0.1	5
440	Applying Cefepime Population Pharmacokinetics to Critically Ill Patients Receiving Continuous Renal Replacement Therapy. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0161121.	3.2	4
441	Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study). International Journal of Antimicrobial Agents, 2021, 58, 106466.	2.5	12
442	¿En qué ayuda el antibiograma al médico clínico en la atención de sus pacientes?. Revista Chilena De Infectología, 0, 21, .	0.1	0
443	Clinical Pharmacology of Antimicrobial Agents: 2.PK/PD in Experimental Models. Japanese Journal of Clinical Pharmacology and Therapeutics, 2005, 36, 173-176.	0.1	0
444	Evaluation of TDM System for Setting of Initial Anti-MRSA Drug Dosages by Pharmacists at Two Hospitals. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2006, 32, 985-996.	0.1	5
445	Dose Adjustment and Pharmacokinetics of Antibiotics in Severe Sepsis and Septic Shock. , 2007, , 122-146.		1
446	é†äæ²»ç™,é~äÿä«äšäã,«ä†äã,³ä†—ä†©ä†«ä³ä«ç™æ³•ç™é†ä«æèëž. Journal of the Japanese Society of Intensive Care Medicine, 2010, 61, 101-106.		0
447	Dose Adjustment and Pharmacodynamic Considerations for Antibiotics in Severe Sepsis and Septic Shock. , 2008, , 97-136.		2
448	ANTIBACTERIAL THERAPEUTIC AGENTS. , 2009, , 3178-3227.		5
449	Mechanisms of Resistance in Haemophilus influenzae and Moraxella catarrhalis. , 2009, , 783-801.		0
451	Mechanisms of action. , 2010, , 1288-1307.		0
453	Fluctuation in PK/PD Parameters and Adverse Reactions of Vancomycin. Iryo Yakugaku (Japanese) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	0.1	0
454	Evaluation of Japanese GFR Estimation Equation for Setting Initial Dose of Vancomycin-Comparison with Cockcroft & Gault equation-. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.1	0
456	Antimicrobial Pharmacokinetics and Pharmacodynamics in the Treatment of Nosocomial Gram-negative Infections. Advances in Pharmacoepidemiology & Drug Safety, 2013, 01, .	0.1	1

#	ARTICLE	IF	CITATIONS
457	Antibiotics in Treatment of Periprosthetic Joint Infections. , 2014, , 107-123.		0
458	Study of VCM 2 $\hat{1}/4$ g/m <sup>2</sup> of <i>S. aureus</i> in the Micro Scan Walk Away POS series panel. Japanese Journal of Medical Technology, 2014, 63, 90-93.	0.0	0
459	Clinical Testing of a New Drug. Springer Series in Pharmaceutical Statistics, 2017, , 1-18.	0.0	0
460	Antibiotic Pharmacodynamics. , 2018, , 17-29.		2
461	Antibiotic and Antifungal Therapy in the ICU. , 2018, , 373-389.		1
462	Optimizing the management of Pseudomonas aeruginosa infections with tools for the detection of resistance mechanisms and pharmacokinetic/pharmacodynamic (PK/PD) analysis. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2019, 37, 623-625.	0.5	1
463	Challenges of Vancomycin Dosing and Therapeutic Monitoring in Neonates. Journal of Pediatric Pharmacology and Therapeutics, 2020, 25, 476-484.	0.5	10
464	Therapeutic Drug Monitoring of Antibiotics: Defining the Therapeutic Range. Therapeutic Drug Monitoring, 2022, 44, 19-31.	2.0	31
465	Should Therapeutic Monitoring of Vancomycin Based on Area under the Curve Become Standard Practice for Patients with Confirmed or Suspected Methicillin-Resistant Infection?. Canadian Journal of Hospital Pharmacy, 2020, 73, 232-237.	0.1	3
466	Clinical Testing of a New Drug. Springer Series in Pharmaceutical Statistics, 2021, , 1-21.	0.0	0
467	Enhanced loading dose of teicoplanin for three days is required to achieve a target trough concentration of 20 $\hat{1}/4$ g/mL in patients receiving continuous venovenous haemodiafiltration with a low flow rate. Journal of Infection and Chemotherapy, 2022, 28, 232-237.	1.7	4
468	Appropriate Use of Glycopeptide Antibiotics and Therapeutic Drug Monitoring for Invasive Infections. Korean Journal of Medicine, 2021, 96, 463-477.	0.3	0
469	Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Journal of Antimicrobial Chemotherapy, 2022, 77, 869-879.	3.0	23
470	Modelled Target Attainment after Temocillin Treatment in Severe Pneumonia: Systemic and Epithelial Lining Fluid Pharmacokinetics of Continuous versus Intermittent Infusions. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0205221.	3.2	13
471	Pharmacokinetics of Cefazolin in Patients With Obesity Undergoing Surgery Requiring Cardiopulmonary Bypass. Journal of Cardiothoracic and Vascular Anesthesia, 2022, 36, 2942-2947.	1.3	2
472	Validation of Vancomycin Area under the Concentrationâ€”Time Curve Estimation by the Bayesian Approach Using One-Point Samples for Predicting Clinical Outcomes in Patients with Methicillin-Resistant Staphylococcus aureus Infections. Antibiotics, 2022, 11, 96.	3.7	20
473	Concise Clinical Review of Hematologic Toxicity of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Role of Mitochondria. Tuberculosis and Respiratory Diseases, 2022, 85, 111-121.	1.8	8
476	Pharmacokinetics and pharmacokinetic/pharmacodynamic-based dosing regimens of long-acting oxytetracycline in Nile tilapia (Oreochromis niloticus) broodstock to minimize selection of drug resistance. Aquaculture, 2022, 557, 738302.	3.5	1

#	ARTICLE	IF	CITATIONS
477	Population pharmacokinetics and dosing optimization of mezlocillin in neonates and young infants. <i>Journal of Antimicrobial Chemotherapy</i> , 0, .	3.0	2
478	The primary pharmacology of ceftazidime/avibactam: <i>in vivo</i> translational biology and pharmacokinetics/pharmacodynamics (PK/PD). <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2341-2352.	3.0	9
479	Harnessing Clinical Trial and Real-World Data Towards an Understanding of Sex Effects on Drug Pharmacokinetics, Pharmacodynamics and Efficacy. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	4
480	Optimizing Antimicrobial Therapy by Integrating Multi-Omics With Pharmacokinetic/Pharmacodynamic Models and Precision Dosing. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	2
481	Using Machine Learning To Define the Impact of Beta-Lactam Early and Cumulative Target Attainment on Outcomes in Intensive Care Unit Patients with Hospital-Acquired and Ventilator-Associated Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	3.2	12
482	Population Pharmacokinetics of Temocillin Administered by Continuous Infusion in Patients with Septic Shock Associated with Intra-Abdominal Infection and Ascitic Fluid Effusion. <i>Antibiotics</i> , 2022, 11, 898.	3.7	4
483	Norvancomycin for the treatment of central nervous system MRSA infections: A randomized controlled trial. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 177, 106266.	4.0	2
484	Binding of temocillin to plasma proteins <i>in vitro</i> and <i>in vivo</i> : the importance of plasma protein levels in different populations and of co-medications. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2742-2753.	3.0	3
485	Reproducible Quantification of Unbound Fractions of Four Beta-lactam Antibiotics: Ultrafiltration versus Microdialysis of Spiked Healthy Donor Plasma. <i>Therapeutic Drug Monitoring</i> , 2022, Publish Ahead of Print, .	2.0	0
486	Efficacy and safety of high-dose esomeprazole+amoxicillin dual therapy for <i>Helicobacter pylori</i> rescue treatment: a multicenter, prospective, randomized, controlled trial. <i>Chinese Medical Journal</i> , 2022, 135, 1707-1715.	2.3	11
487	Tissue Penetration of Antimicrobials in Intensive Care Unit Patients: A Systematic Review”Part I. <i>Antibiotics</i> , 2022, 11, 1164.	3.7	9
488	Tissue Penetration of Antimicrobials in Intensive Care Unit Patients: A Systematic Review”Part II. <i>Antibiotics</i> , 2022, 11, 1193.	3.7	7
489	Meropenem Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children Receiving Continuous Renal Replacement Therapy. <i>Clinical Pharmacokinetics</i> , 0, .	3.5	0
490	Comparison of Open-Access, Trough-Only Online Calculators Versus Trapezoidal Method for Calculation of Vancomycin Area Under the Curve (AUC). <i>Annals of Pharmacotherapy</i> , 0, , 106002802211388.	1.9	2
491	Evaluation of drug prescribing patterns and therapeutic drug monitoring practice using electronic medical records. <i>Scientific Reports</i> , 2022, 12, .	3.3	0
492	Vonoprazan and high-dose amoxicillin dual therapy for <i>Helicobacter pylori</i> first-line eradication: A single-arm, interventional study. <i>JGH Open</i> , 2023, 7, 55-60.	1.6	5
493	<scp>VANCOMycin</scp> dose adjustments comparing trough levels to the ratio of the area under de curve to the minimum inhibitory concentration method using a <scp>BAYESian</scp> approach: A feasibility study. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 2335-2344.	1.5	2
494	Beta-lactam target attainment and associated outcomes in patients with bloodstream infections. <i>International Journal of Antimicrobial Agents</i> , 2023, 61, 106727.	2.5	14

#	ARTICLE	IF	CITATIONS
495	Evaluation of cefuroxime concentration in the intra- and extrathecal compartments of the lumbar spine – an experimental porcine study. <i>British Journal of Pharmacology</i> , 0, , .	5.4	0
496	What Is the Best Vancomycin Therapeutic Drug Monitoring Parameter to Assess Efficacy? A Critical Review of Experimental Data and Assessment of the Need for Individual Patient Minimum Inhibitory Concentration Value. <i>Microorganisms</i> , 2023, 11, 567.	3.6	1
497	Predictive Factors of Piperacillin Exposure and the Impact on Target Attainment after Continuous Infusion Administration to Critically Ill Patients. <i>Antibiotics</i> , 2023, 12, 531.	3.7	0
498	Optimizing pharmacotherapy regimens in adult patients receiving extracorporeal membrane oxygenation: A narrative review for clinical pharmacists. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2023, 6, 621-631.	1.0	1
499	Population pharmacokinetics and dosing optimisation of imipenem in critically ill patients. <i>European Journal of Hospital Pharmacy</i> , 0, , ejhpharm-2022-003403.	1.1	1
500	A retrospective analysis to estimate trough concentrations of teicoplanin in patients with suspected or documented Gram-positive infections. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 0, 59, .	1.2	0
501	Bayesian prediction-based individualized dosing of anti-methicillin-resistant <i>Staphylococcus aureus</i> treatment: Recent advancements and prospects in therapeutic drug monitoring. , 2023, 246, 108433.		0
502	Beta-Lactam Dose Optimisation in the Intensive Care Unit: Targets, Therapeutic Drug Monitoring and Toxicity. <i>Antibiotics</i> , 2023, 12, 870.	3.7	7
503	Efficacy of meropenem extended infusion vs intermittent bolus monotherapy and in combination with colistin against <i>Pseudomonas aeruginosa</i> biofilm. <i>International Journal of Antimicrobial Agents</i> , 2023, 62, 106856.	2.5	1
504	A three-level model for therapeutic drug monitoring of antimicrobials at the site of infection. <i>Lancet Infectious Diseases</i> , The, 2023, 23, e445-e453.	9.1	8
505	Individualized antibiotic dosage regimens for patients with augmented renal clearance. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	3
506	Population pharmacokinetics and model-based dosing optimization of teicoplanin in elderly critically ill patients with pneumonia. <i>Journal of Critical Care</i> , 2023, 78, 154402.	2.2	1
507	A Modified 14-Day Dual Therapy with Vonoprazan and Amoxicillin Amplified the Advantages Over Conventional Therapies for Eradication of <i>Helicobacter pylori</i> : A Non-Inferiority Clinical Trial. <i>Infection and Drug Resistance</i> , 0, Volume 16, 5637-5645.	2.7	5
508	Pharmacokinetics of cefpirome following intravenous and intramuscular administrations in healthy and febrile sheep ( <i>Ovis aries</i> ). <i>Indian Journal of Animal Sciences</i> , 2023, 93, .	0.2	0
510	Potential benefits of therapeutic drug monitoring for beta-lactam antibiotics in augmented renal clearance patients: a case report. <i>Canadian Journal of Physiology and Pharmacology</i> , 0, , .	1.4	0
511	Defining standard and high dosages for $\beta$ -lactam agents administered by intermittent, prolonged or continuous infusion: a PK/PD simulation study. <i>Journal of Antimicrobial Chemotherapy</i> , 2023, 78, 2762-2769.	3.0	1
513	Cefepime Daily Exposure and the Associated Impact on the Change in Sequential Organ Failure Assessment Scores and Vasopressors Requirement in Critically Ill Patients Using Repeated-Measures Mixed-Effect Modeling. , 2023, 5, e0993.		1
514	Population pharmacokinetics and target attainment analysis of vancomycin after intermittent dosing in adults with cystic fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , 0, , .	3.2	0

#	ARTICLE	IF	CITATIONS
515	Therapeutic drug monitoring of glycopeptide antimicrobials: An overview of liquid chromatography-tandem mass spectrometry methods. <i>Journal of Mass Spectrometry and Advances in the Clinical Lab</i> , 2024, 31, 33-39.	2.4	0
516	Population pharmacokinetics and dosing simulations of total and unbound temocillin in the plasma and CSF of neurocritically ill patients with external ventricular drain-related cerebral ventriculitis. <i>Journal of Antimicrobial Chemotherapy</i> , 2024, 79, 429-442.	3.0	0
517	Translational PK/PD for the Development of Novel Antibiotics—A Drug Developer's Perspective. <i>Antibiotics</i> , 2024, 13, 72.	3.7	0
518	Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing. <i>Clinical Microbiology Reviews</i> , 0, , .	13.6	0
519	Mortality of continuous infusion versus intermittent bolus of meropenem: a systematic review and meta-analysis of randomized controlled trials. <i>Frontiers in Microbiology</i> , 0, 15, .	3.5	0
520	Vonoprazan-amoxicillin dual therapy with different amoxicillin dosages for treatment-naïve patients of <i>Helicobacter pylori</i> infection in China: a prospective, randomized controlled study. <i>European Journal of Gastroenterology and Hepatology</i> , 2024, 36, 712-719.	1.6	0